Risk Factors and Outcomes of Patients with Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection

References

• Raúl Recio MM, Esther V, Jennifer V, María Ángeles O, Jaime L-T, Fernando C. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence. Antimicrob Agents Chemother. 2020;64(2):e01759–01719. doi:10.1128/AAC.01759-19
   PubMed Web of Science ®Google Scholar
• Gaynes REJ. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–854. doi:10.1086/432803
   PubMed Web of Science ®Google Scholar
• Lodise TP, Bassetti M, Ferrer R, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther. 2022;20(5):707–719. doi:10.1080/14787210.2022.2020099
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen X-L, Huang A-W, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Em Microbes Infections. 2019;5(1):1–6.
   Google Scholar
• Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017. N Engl J Med. 2020;382(14):1309–1319. doi:10.1056/NEJMoa1914433
   PubMed Web of Science ®Google Scholar
• Montero MM, Lopez Montesinos I, Knobel H, et al. Risk factors for mortality among patients with Pseudomonas aeruginosa bloodstream infections: what is the influence of XDR phenotype on outcomes? J Clin Med. 2020;9(2):514. doi:10.3390/jcm9020514
   PubMed Web of Science ®Google Scholar
• Buehrle DJ, Shields RK, Clarke LG, Potoski BA, Clancy CJ, Nguyen MH. Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure. Antimicrob Agents Chemother. 2017;61(1). doi:10.1128/AAC.01243-16
   PubMed Web of Science ®Google Scholar
• Recio R, Viedma E, Gonzalez-Bodi S, et al. Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia. Int J Antimicrob Agents. 2021;58(6):106450. doi:10.1016/j.ijantimicag.2021.106450
   PubMed Web of Science ®Google Scholar
• Teelucksingh K, Shaw E. Clinical characteristics, appropriateness of empiric antibiotic therapy, and outcome of Pseudomonas aeruginosa bacteremia across multiple community hospitals. Eur J Clin Microbiol Infect Dis. 2021;41(1):53–62. doi:10.1007/s10096-021-04342-y
   PubMed Web of Science ®Google Scholar
• Julia S, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16(3):128–140. doi:10.1016/0196-6553(88)90053-3
   PubMed Web of Science ®Google Scholar
• Performance CLSI. Standards for Antimicrobial Susceptibility Testing. 31 ed. Clinical and Laboratory Standards Institute; 2021.
   Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang Y, Wan Q. Pseudomonas aeruginosa bacteremia among liver transplant recipients. Infect Drug Resist. 2018;11:2345–2356. doi:10.2147/IDR.S180283
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Y, Zeng J, et al. Risk factors for mortality of inpatients with Pseudomonas aeruginosa bacteremia in China: impact of resistance profile in the mortality. Infect Drug Resist. 2020;13:4115–4123. doi:10.2147/IDR.S268744
   PubMed Web of Science ®Google Scholar
• Righi E, Peri AM, Harris PNA, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use systematic review and meta-analysis. J Antimicrobial Chemother;2016;dkw459. doi:10.1093/jac/dkw459
   Web of Science ®Google Scholar
• Shi Q, Huang C, Xiao T, Wu Z, Xiao Y. A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and -non-susceptible infections. Antimicrob Resist Infect Control. 2019;8(1). doi:10.1186/s13756-019-0520-8
   Google Scholar
• Raman G, Avendano EE, Chan J, Merchant S, Puzniak L. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2018;7:79. doi:10.1186/s13756-018-0370-9
   PubMed Web of Science ®Google Scholar
• Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis. 2019;6(2):109–119. doi:10.1016/j.gendis.2019.04.001
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Antimico Resistance. 2002;34(5):634–640.
   Google Scholar
• Geisinger E, Isberg RR. Interplay between antibiotic resistance and virulence during disease promoted by multidrug-resistant bacteria. J Infect Dis. 2017;215(suppl_1):S9–S17. doi:10.1093/infdis/jiw402
   PubMedGoogle Scholar
• Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4). doi:10.1128/CMR.00031-19
   PubMed Web of Science ®Google Scholar
• Del Barrio-Tofino E, Sanchez-Diener I, Zamorano L, et al. Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. J Antimicrob Chemother. 2019;74(11):3217–3220. doi:10.1093/jac/dkz346
   PubMed Web of Science ®Google Scholar
• Breidenstein EB, de la Fuente-Nunez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19(8):419–426. doi:10.1016/j.tim.2011.04.005
   PubMed Web of Science ®Google Scholar
• Del Barrio-Tofino E, Lopez-Causape C, Cabot G, et al. Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa Isolates from Spain. Antimicrob Agents Chemother. 2017;61(11). doi:10.1128/AAC.01589-17
   Web of Science ®Google Scholar
• Del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, et al. Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. J Antimicrobial Chemother. 2019;74(7):1825–1835. doi:10.1093/jac/dkz147
   PubMed Web of Science ®Google Scholar
• Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents. 2015;45(6):568–585. doi:10.1016/j.ijantimicag.2015.03.001
   PubMed Web of Science ®Google Scholar
• Viasus D, Puerta-Alcalde P, Cardozo C, et al. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection. Clin Microbiol Infection. 2020;26(3):345–350. doi:10.1016/j.cmi.2019.07.002
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lin Q, Liu L, et al. Risk factors and outcomes of antibiotic-resistant Pseudomonas aeruginosa bloodstream infection in adult patients with acute leukemia. Clin Infectious Dis. 2020;71(Supplement_4):S386–S393. doi:10.1093/cid/ciaa1522
   PubMedGoogle Scholar
• Marin M, Gudiol C, Ardanuy C, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. J Infection. 2014;69(5):417–423. doi:10.1016/j.jinf.2014.05.018
   PubMed Web of Science ®Google Scholar
• Babich T, Naucler P, Valik JK, et al. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. Int J Antimicrob Agents. 2020;55(2):105847. doi:10.1016/j.ijantimicag.2019.11.004
   PubMed Web of Science ®Google Scholar
• Recio R, Villa J, Viedma E, Orellana MÁ, Lora-Tamayo J, Chaves F. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: facing the perfect storm. Int J Antimicrob Agents. 2018;52(2):172–179. doi:10.1016/j.ijantimicag.2018.03.018
   PubMed Web of Science ®Google Scholar
• Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010;54(9):3717–3722. doi:10.1128/AAC.00207-10
   PubMed Web of Science ®Google Scholar
• Satlin MJ. Languid uptake of ceftazidime-avibactam for carbapenem-resistant gram-negative infections and continued reliance on polymyxins. Clin Infect Dis. 2021;72(4):622–625. doi:10.1093/cid/ciaa065
   PubMed Web of Science ®Google Scholar
• Motsch J. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799–1808. doi:10.1093/cid/ciz530
   PubMed Web of Science ®Google Scholar
• Kadri SS, Hohmann SF, Orav EJ, et al. Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections. Clin Infect Dis. 2015;60(1):79–87. doi:10.1093/cid/ciu741
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Chuncharunee A, Maluangnon C, Taweesakulvashra T, Tiamsak P. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia. Int J Antimicrob Agents. 2018;52(6):828–834. doi:10.1016/j.ijantimicag.2018.09.008
   PubMed Web of Science ®Google Scholar
• Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(1):29–39. doi:10.1093/jac/dkw377
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infectious Dis. 2021;72(7):1109–1116. doi:10.1093/cid/ciab295
   PubMedGoogle Scholar
• Lee CH, Su TY, Ye JJ, et al. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. J Microbiol Immunol Infect. 2017;50(5):677–683. doi:10.1016/j.jmii.2015.06.003
   PubMedGoogle Scholar
• Pena C, Suarez C, Gozalo M, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother. 2012;56(3):1265–1272. doi:10.1128/AAC.05991-11
   PubMed Web of Science ®Google Scholar
• Lin K-Y, Lauderdale T-L, Wang J-T, Chang S-C. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: prevalence, risk factors, and impact on outcome of infections. J Microbiol Immunol Infection. 2016;49(1):52–59. doi:10.1016/j.jmii.2014.01.005
   Web of Science ®Google Scholar
• Jeong SJ, Yoon SS, Bae IK, Jeong SH, Kim JM, Lee K. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome. Diagn Microbiol Infect Dis. 2014;80(2):130–135. doi:10.1016/j.diagmicrobio.2014.07.003
   PubMed Web of Science ®Google Scholar
• Raman G, Avendano E, Berger S, Menon V. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis. BMC Infect Dis. 2015;15:395. doi:10.1186/s12879-015-1123-5
   PubMed Web of Science ®Google Scholar